Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

SML0653

Sigma-Aldrich

Capecitabine

≥98% (HPLC)

Sinonimo/i:

5′-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine, Ro-9-1978

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

10 MG
63,30 €
50 MG
140,00 €

63,30 €

Per informazioni sulla disponibilità, contatta il Servizio Clienti.
Richiedi un ordine bulk
Tutte le immagini(1)

Scegli un formato

Cambia visualizzazione
10 MG
63,30 €
50 MG
140,00 €

About This Item

Formula empirica (notazione di Hill):
C15H22FN3O6
Numero CAS:
154361-50-9
Peso molecolare:
359.35
Numero MDL:
MFCD00930626
Codice UNSPSC:
12352200
ID PubChem:
329825576
NACRES:
NA.77

63,30 €

Per informazioni sulla disponibilità, contatta il Servizio Clienti.
Richiedi un ordine bulk

Saggio

≥98% (HPLC)

Stato

powder

Attività ottica

[α]/D +80 to +100°, c = 0.5 in methanol

Colore

white to beige

Solubilità

H2O: 10 mg/mL, clear (warmed)

Temperatura di conservazione

2-8°C

Stringa SMILE

O[C@H]1[C@@H](O)[C@H](N2C(N=C(NC(OCCCCC)=O)C(F)=C2)=O)O[C@@H]1C

InChI

1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1
GAGWJHPBXLXJQN-UORFTKCHSA-N

Informazioni sul gene

human ... TYMS(7298)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

Capecitabine has been used:

  • in combination with gemcitabine to achieve glutamine deprivation by enhancing the sensitivity of expression in pancreatic ductal adenocarcinoma (PDAC) cells to inhibitors of glutamine metabolism and study its effect on PDAC cell survival[1]
  • to study the drug metabolic function in a two-organ microfluidic system[2]
  • as an anti-cancer agent to study its cytotoxic activity alone or in combination with B87 on cancer cells[3]

Azioni biochim/fisiol

Capecitabine is an anti-cancer drug, a prodrug of doxifluridine, metabolized to 5-fluorouracil at the tumor site.
Capecitabine is an anti-cancer drug, a prodrug of doxifluridine, metabolized to 5-fluorouracil at the tumor site. The activation of capecitabine follows a pathway with three enzymatic steps and two intermediary metabolites, 5′-Deoxy-5-fluorocytidine (5′-DFCR) and 5′-Deoxy-5-fluorouridine (5′-DFUR), to form 5-fluorouracil.

Pittogrammi

Health hazard
GHS08

Avvertenze

Danger

Indicazioni di pericolo

H341,H350,H360FD

Classi di pericolo

Carc. 1B - Muta. 2 - Repr. 1B

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
0000217945
0000194809
104M4745V
033M4736V

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 6

1 of 6

Docetaxel purum, ≥97.0% (HPLC)

Sigma-Aldrich

01885

Docetaxel

Letrozole ≥98% (HPLC)

Sigma-Aldrich

L6545

Letrozole

Cyclophosphamide Monohydrate A widely used anti-neoplastic agent that also displays immunosuppressant properties.

Sigma-Aldrich

239785

Cyclophosphamide Monohydrate

Exemestane ≥98% (HPLC)

Sigma-Aldrich

PZ0006

Exemestane

2-Fluoroadenosine 97%

Sigma-Aldrich

656402

2-Fluoroadenosine

Cladribine European Pharmacopoeia (EP) Reference Standard

Y0000639

Cladribine

Tim Meyer et al.
European journal of cancer (Oxford, England : 1990), 50(5), 902-911 (2014-01-22)
Cytotoxic chemotherapy is widely used for advanced, unresectable pancreatic and other gastrointestinal foregut neuroendocrine tumours (NETs) and the most commonly used regimen combines 5-fluorouracil with streptozocin. The NET01 trial was designed to investigate whether capecitabine combined with streptozocin was an
Mitsuhiro Tomoda et al.
Anticancer research, 34(1), 191-194 (2014-01-10)
Unresectable metastatic colorectal cancer with very slow tumour growth rate does not necessarily require for strong short-interval chemotherapy. In the present study, we administered monthly chemotherapy and aimed to evaluate the usefulness of the specific treatment schedule in patients with
Takahiro Yamanashi et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 41(1), 107-112 (2014-01-16)
A 77-year-old man who complained of melena was admitted to our department. Colonoscopy revealed a type 2 tumor in the hepatic flexure of the ascending colon. Biopsy examination revealed a poorly differentiated adenocarcinoma. Abdominal computed tomography(CT)revealed 3 tumors within the
Valentina Sini et al.
Tumori, 99(6), 273e-277e (2014-02-08)
This report describes a case of ab initio metastatic HER2-positive breast cancer in a very young patient. The onset of breast cancer at such a young age is uncommon and could delay the diagnosis with unquestionable impact on the prognosis.
Nestor F Esnaola et al.
International journal of radiation oncology, biology, physics, 88(4), 837-844 (2014-03-13)
To evaluate, in a phase 2 study, the safety and efficacy of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer (BRPC or LAPC, respectively). Patients received gemcitabine
Visualizza tutti i documenti correlati

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.